Ruxton Pharmaceuticals, Inc., a pharmaceutical company focused on discovering, developing and marketing drugs for the treatment of neurodegenerative diseases, announced the completion of a $5.2 million financing. Domain Associates, New Enterprise Associates, and Aberdare Ventures co-led this Series A financing. Proceeds from this financing will be used to identify and prepare drugs for clinical studies.
